Trial Profile
A retrospective study of everolimus plus exemestane in patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology